Abstract
The new Italian policy to off-patent products, although similar to recent reforms in other European countries, seems to use some interesting instruments and has achieved significant results in the past 2 years. In particular, the prices of branded products have been reduced for all active ingredients where a generic version is available. However, this strategy may raise some problems in the longer term. Our analysis identified two open issues that might limit the long-term sustainability of the present scheme: the limited diffusion of generics and the reallocation of demand. The first stems from the new regulatory schemes which equate generics to branded off-patent products and exploit their presence only to cut prices. The second is favored by tough price competition that induces large companies to divert demand towards more profitable “me-too drugs.” Solutions exist, but they are not easy to apply because so many difficulties arise when certain aspects of a long-standing equilibrium are modified.
Similar content being viewed by others
References
Ghislandi S, Krulichova I, Garattini L (2004) Pharmaceutical policy in Italy: towards a structural change? Health Policy 72:53–63
Danzon P (2001) Reference pricing: theory and evidence. In Lopez-Casanovas G, Jonsson B (eds) Reference pricing and pharmaceutical policy. Springer Iberica: Barcelona, pp 86–126
Garattini L, Tediosi F (2000) A comparative analysis of generics markets in five European countries. Health Policy 51:149–162
Coscelli A (2000) The importance of doctors’ and patients’ preferences in the prescription decision. J Ind Econ 48:349–369
Danzon P, Chao L (2000) Does regulation drive out competition in pharmaceutical markets? J Law Econ 43:311–357
Lopez-Casanovas G, Puig-Junoy J (2000) Review of the literature on reference pricing. Health Policy 54:87–123
OsMed (2003) Rapporto nazionale OsMed 2003. Italian Ministry of Health. :http://www.ministerosalute.it/medicinali/osmed, accessed 27 September 2004
Puig-Junoy J (2004) Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67:149–165
Armstrong M, Cowan S, Vickers J (1994) Regulatory reforms: Economic analysis and the UK experience. MIT Press: Boston
Martina S, Cornago D, Garattini L (2002) Gruppo di studio I.H.A.G.O. Incentivi ai farmaci generici a livello di ASL: l’osservatorio I.H.A.G.O.” Farma Percorsi Ter 3:71–80
Roberts K (2001) Would we be able to recognize a socially desirable reference pricing system if it bit us on the ankle? In Lopez-Casanovas G, Jonsson B (eds) Reference pricing and pharmaceutical policy. Springer Iberica: Barcelona, pp 161–187
Conflict of interest:
No information supplied.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garattini, L., Ghislandi, S. Off-patent drugs in Italy. Eur J Health Econ 7, 79–83 (2006). https://doi.org/10.1007/s10198-005-0335-9
Issue Date:
DOI: https://doi.org/10.1007/s10198-005-0335-9